Horizon Therapeutics to acquire Viela Bio for $3bn to grow rare disease portfolio
Horizon Therapeutics, an Irish biopharma company, has agreed to acquire Viela Bio, a US-based biotech company, for $53 per share in cash or about $3.05 billion in a move to significantly expand its development pipeline and grow its rare disease medicine portfolio. Viela Bio is focused on developing and commercializing therapies for a wide variety […]